> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-192/
- Published: 2018-08-26T12:00:00.000Z
- Updated: 2026-09-15T00:28:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142206

[**Pharmaceutical Quality Site Visit Program**](https://www.fdaweb.com/pharmaceutical-quality-site-visit-program/)  
*Federal Register* notice: CDER announces the Fiscal Year 2019 CDER Office of Pharmaceutical Quality (OPQ) Staff Experiential Learning Site Visit Program. 08/24/2018

[**Plasma Lyte Not Withdrawn Due to Safety/Efficacy**](https://www.fdaweb.com/plasma-lyte-not-withdrawn-due-to-safety-efficacy/)  
*Federal Register* notice: FDA determines that Plasma – Lyte M And Dextrose 5% and Plasma Lyte and Dextrose 5% were not withdrawn for reasons of safety or effectiveness. 08/24/2018

[**Guide on Hematologic Malignancy and Oncologic Drug Trials**](https://www.fdaweb.com/guide-on-hematologic-malignancy-and-oncologic-drug-trials/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Hematologic Malignancy and Oncologic Disease: Considerations for Use of Placebos and Blinding in Randomized Controlled Clinical Trials for Drug Product Development.” 08/24/2018

[**Info Collection Extension for User Fee Cover Sheet**](https://www.fdaweb.com/info-collection-extension-for-user-fee-cover-sheet/)  
*Federal Register* notice: FDA seeks comments on an information collection extension entitled “Prescription Drug User Fee Cover Sheet; Form FDA 3397.” 08/24/2018  
  
[**Comments Sought on Sunscreen Info Collection**](https://www.fdaweb.com/comments-sought-on-sunscreen-info-collection/)  
*Federal Register* notice: FDA seeks comments on an information collection extension entitled “Sun Protection Factor Labeling and Testing Requirements for Over-the-Counter Sunscreen Drug Products.” 08/23/2018

[**Draft Guide on Osteoarthritis Structural Endpoints**](https://www.fdaweb.com/draft-guide-on-osteoarthritis-structural-endpoints/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Osteoarthritis: Structural Endpoints for the Development of Drugs, Devices, and Biological Products for Treatment.” 08/23/2018

[**Members Sought for Device Advisory Panels**](https://www.fdaweb.com/members-sought-for-device-advisory-panels/)  
*Federal Register* notice: FDA requests nominations for voting members to serve on the Device Good Manufacturing Practice Advisory Committee and device panels of the Medical Devices Advisory Committee. 08/23/2018

[**Danicrine Not Withdrawn Due to Safety/Efficacy**](https://www.fdaweb.com/danicrine-not-withdrawn-due-to-safety-efficacy/)  
*Federal Register* notice: FDA determines that Danocrine (danazol) Capsules, 50mg, 100mg, and 200mg, were not withdrawn from sale for reasons of safety or effectiveness. 08/23/2018